)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Medigene
Medigene (MDG1) investor relations material
Medigene Status Update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Status Update summary27 Nov, 2024
Strategic refocus and organizational realignment
Capital allocation prioritizes high-return R&D, focusing on off-the-shelf TCR-guided therapies, especially MDG3010 in partnership with WuXi Biologics.
Autologous cell therapy programs, except MDG1015, are paused; MDG1015's phase one trial is delayed pending partnerships or financing, with a CTA submission to EMA planned for Q4 2024.
Organizational realignment includes a 40% headcount reduction and cost-saving measures to align with the updated R&D focus.
Financial guidance and cash runway extend to July 2025, with €9.5M in cash and equivalents as of September 30, 2024.
All financing and strategic options, including a potential sale, are being evaluated to secure the long-term future.
Pipeline and partnership updates
MDG3010, a bispecific TCR-TCE, is the primary focus, with proof-of-principle data expected in H2 2025.
Partnership with WuXi Biologics involves joint development and a 50/50 economic split until lead candidate selection.
Preclinical autologous programs (MDG2021, MDG2011, MDG2012) are paused, with partnering sought for further advancement.
Multiple partnerships with BioNTech, Regeneron, and WuXi Biologics validate the platform and provide milestone and royalty opportunities.
Milestone payments from Regeneron and BioNTech depend on their clinical progress; Regeneron has initiated a trial in China.
Technology and platform innovation
Proprietary end-to-end platform generates best-in-class, specific, sensitive, and safe (3S) TCRs for multiple modalities.
Platform advancements include rapid CD8+ cell manufacturing, off-the-shelf TCR-guided modalities, and broadening of the IP portfolio.
3S TCRs offer superior specificity, safety, and efficacy compared to antibody-based approaches, with resistance to antigen shedding and optimal affinity.
Discovery modules leverage healthy donor pools and advanced screening to identify high-affinity, safe TCRs.
Continued innovation in TCR generation and platform development supports future pipeline expansion.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Medigene
- Medigene's next-gen TCR therapies advance to clinic with key milestones expected through 2027.MDG1
R&D Event - TCR-T pipeline progress, new partnerships, and financing extend cash runway into July 2025.MDG1Q3 2024
- Revenue up 46% and cash runway extended to July 2025; future funding remains critical.MDG1H1 2024
Medigene
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Medigene AG is a biotechnology company specializing in the development of T cell-based immunotherapies for cancer treatment. The company focuses on engineered T cell receptors (TCRs) and dendritic cell vaccines to enhance the body's immune response against tumors. Its research and development efforts aim to create innovative therapies that improve targeted cancer treatment options. The company is headquartered in Planegg, Germany, and its shares are listed on the Frankfurt Stock Exchange (FSE).